Abstract
A 38-year-old woman was diagnosed with phase 2 chronic hepatitis B without delta-agent (HBeAg+) with a high biochemical and viral load and significant liver fibrosis (F2) five years after renal allotransplantation for a chronic kidney disease stage 5 resulting from a congenital urogenital abnormality (left renal hypoplasia). This woman was switched from lamivudine, the first-generation nucleoside analogue, that she received for 6 years, to entecavir (after a 4-year interval). However, the development of the resistance to entecavir forced to switch to tenofovir. A positive virological response was achieved as demonstrated by the lack of the isolation of hepatitis B virus (HBV) DNA one year after starting treatment. Yet, HBV is not detected. In addition, F2 fibrosis down-graded to F0 by the METAVIR score (as demonstrated by liver fibroelastometry). The woman is currently being followed-up. KEYWORDS: chronic hepatitis B, chronic kidney disease, renal allotransplantation, antiviral treatment, nucleoside analogues. FOR CITATION: Omarova Kh.G., Makashova V.V. Chronic hepatitis B in a woman with chronic kidney disease. Russian Medical Inquiry. 2020;4(11):710–713. DOI: 10.32364/2587-6821-2020-4-11-710-713.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have